GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

Specifically, the current investigations in his lab involve the following research projects: the signaling mechanisms of myocardial fibrosis; the mechanism of heart failure in cancer patients, and the ...

GSK’s £3 billion peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key ...

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with ...

However, their precursor proteins (pro-BDNF and pro-NGF) induce apoptosis by coupling to the sortilin and the p75 neurotrophin receptor death-signaling ... activation and GSK-3β inhibition ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

(RTTNews) - GSK plc (GSK.L) reported that its third quarter ... reflecting a charge of 1.8 billion pounds or $2.3 billion in relation to the Zantac settlement. Loss attributable to shareholders ...

GSK: HIV Presentation Highlights Long-Duration Dosing Options to Help Mitigate 2028 Patent Losses GSK hosted an analyst presentation on its HIV segment (close to 20% of total sales) signaling ...

GSK plc GSK reported third-quarter 2024 core earnings ... Core research and development expenses rose 3% to £1.43 billion, driven by continued investment by management in pipeline advancement.

Risks include margin pressure and regulatory uncertainties, especially as margins declined from 24.3% in Q2 2023 to 16.5% in Q2 2024. GSK plc (NYSE:GSK) is a biopharmaceutical company with a long ...